MY145936A - Solid state forms of racemic ilaprazole - Google Patents

Solid state forms of racemic ilaprazole

Info

Publication number
MY145936A
MY145936A MYPI20092734A MYPI20092734A MY145936A MY 145936 A MY145936 A MY 145936A MY PI20092734 A MYPI20092734 A MY PI20092734A MY PI20092734 A MYPI20092734 A MY PI20092734A MY 145936 A MY145936 A MY 145936A
Authority
MY
Malaysia
Prior art keywords
solid state
racemic ilaprazole
state forms
ilaprazole
methyl
Prior art date
Application number
MYPI20092734A
Inventor
John M Brackett
David T Jonaitis
Lai Wei
Liu Jih Hua
Stephan D Parent
Shen Jinyu
Original Assignee
Il Yang Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharmaceutical Company Ltd filed Critical Il Yang Pharmaceutical Company Ltd
Publication of MY145936A publication Critical patent/MY145936A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

THE INVENTION RELATES TO CRYSTALLINE FORMS OF RACEMIC ILAPRAZOLE, 2[[(4-METHOXY-3-METHYL- 2-PYRIDINYL)-METHYL]SULFINYL]-5-(1-H-PYRROL-1-YL) 1 H BENZIMIDAZOLE. THE INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITION FOR INHIBITING GASTRIC ACID SECRETION COMPRISING A CRYSTALLINE FORM OF ILAPRAZOLE ACCORDING TO THE INVENTION IN AN AMOUNT EFFECTIVE TO INHIBIT GASTRIC ACID SECRETION AND A PHARMACEUTICALLY ACCEPTABLE CARRIER. THE INVENTION ALSO PROVIDES METHODS OF TREATMENT FOR VARIOUS ACID-RELATED GASTROINTESTINAL (G1) DISORDERS.
MYPI20092734A 2006-12-29 2007-12-28 Solid state forms of racemic ilaprazole MY145936A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87760806P 2006-12-29 2006-12-29
US88749907P 2007-01-31 2007-01-31

Publications (1)

Publication Number Publication Date
MY145936A true MY145936A (en) 2012-05-31

Family

ID=39313094

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20092733A MY146462A (en) 2006-12-29 2007-12-28 Crystalline forms of solvated ilaprazole
MYPI20092734A MY145936A (en) 2006-12-29 2007-12-28 Solid state forms of racemic ilaprazole

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MYPI20092733A MY146462A (en) 2006-12-29 2007-12-28 Crystalline forms of solvated ilaprazole

Country Status (19)

Country Link
US (4) US7989632B2 (en)
EP (2) EP2102192B1 (en)
JP (2) JP5315253B2 (en)
KR (3) KR20110091594A (en)
CN (2) CN101687848B (en)
AU (2) AU2007341992B2 (en)
CA (2) CA2674358C (en)
DK (1) DK2102192T3 (en)
ES (1) ES2398846T3 (en)
HK (2) HK1140483A1 (en)
IL (2) IL199234A (en)
MX (2) MX2009006529A (en)
MY (2) MY146462A (en)
NO (2) NO20092398L (en)
NZ (2) NZ577129A (en)
PL (1) PL2102192T3 (en)
PT (1) PT2102192E (en)
RU (2) RU2466129C2 (en)
WO (2) WO2008083333A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144600B1 (en) * 2009-12-08 2012-05-16 일양약품주식회사 Process for Preparing and Conversion of Ilaprazole Crystalline Form A, B
CN103204843B (en) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium ethylate and preparation method thereof
CN103204842B (en) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium hydrate and preparation method thereof
WO2013114232A1 (en) * 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN102746277B (en) * 2012-06-21 2014-05-14 丽珠医药集团股份有限公司 Crystal-form ilaprazole sodium and preparation method thereof
CN102746275B (en) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 Crystallization-type ilaprazole sodium and preparation method thereof
CN103172618B (en) * 2013-02-27 2014-09-03 丽珠医药集团股份有限公司 Ilaprazole crystal form and preparation method thereof
CN104370886B (en) * 2014-11-18 2016-05-18 宁夏康亚药业有限公司 Iprazole crystal formation and its preparation method and application
CN105055342A (en) * 2015-08-13 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer
CN105055343A (en) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 Ilaprazole sodium composition freeze-dried powder injection serving as medicine for treating stomach diseases
CN106749191A (en) * 2016-12-10 2017-05-31 珠海保税区丽珠合成制药有限公司 Ilaprazole crystal form II and preparation method thereof
KR101961028B1 (en) * 2017-10-12 2019-03-21 중앙대학교 산학협력단 Pharmaceutical composition for preventing or treating acute gastritis comprising ilaprazole
KR102332996B1 (en) * 2020-04-13 2021-12-01 중앙대학교 산학협력단 Pharmaceutical composition for preventing or treating ileus comprising Ilaprazole
KR20220065235A (en) 2020-11-13 2022-05-20 주식회사 파마코스텍 Process for the crystalline form of Ilaprazole
KR102250509B1 (en) * 2020-12-09 2021-05-11 유니셀랩 주식회사 Novel co-crystal of ilaprazole/xylitol
KR20210019469A (en) 2021-02-02 2021-02-22 주식회사 파마코스텍 Crystalline form of Ilaprazole sodium and its new process

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179401B1 (en) * 1994-02-28 1999-03-20 송택선 Novel 5-pyrrolyl-2-pyridylmethylsulfanilbenzimidazole derivatives
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
RU2232159C2 (en) * 1999-07-29 2004-07-10 Регентский Совет Университета Калифорнии Derivatives of benzimidazole and pharmaceutical compositions comprising prodrug of proton pump inhibitor
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
KR20040093187A (en) 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 Lansoprozole polymorphs and processes for preparation thereof
JP4837722B2 (en) 2005-03-25 2011-12-14 リブゾン ファーマシューティカル グループ インク． Substituted sulfoxide compounds, methods for their preparation, and methods for their use
EP1879577A1 (en) * 2005-05-04 2008-01-23 AstraZeneca AB Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux

Also Published As

Publication number Publication date
AU2007341984B2 (en) 2012-07-05
HK1140484A1 (en) 2010-10-15
CN101687849A (en) 2010-03-31
IL199242A (en) 2013-10-31
US8592600B2 (en) 2013-11-26
CA2674347A1 (en) 2008-07-10
JP5315254B2 (en) 2013-10-16
US20110082174A1 (en) 2011-04-07
NZ577509A (en) 2012-01-12
RU2466129C2 (en) 2012-11-10
EP2102192B1 (en) 2012-11-14
PT2102192E (en) 2013-01-23
RU2009122241A (en) 2011-02-10
KR20110091594A (en) 2011-08-11
US20110046184A1 (en) 2011-02-24
US7999110B2 (en) 2011-08-16
EP2102191B1 (en) 2012-11-21
KR101052387B1 (en) 2011-07-28
JP2010514807A (en) 2010-05-06
AU2007341992B2 (en) 2012-07-05
JP2010514806A (en) 2010-05-06
AU2007341984A1 (en) 2008-07-10
CN101687849B (en) 2013-05-29
US8592599B2 (en) 2013-11-26
DK2102192T3 (en) 2013-03-04
KR20090086615A (en) 2009-08-13
CN101687848B (en) 2013-05-15
WO2008083333A1 (en) 2008-07-10
US7989632B2 (en) 2011-08-02
NO20092398L (en) 2009-09-28
CA2674358A1 (en) 2008-07-10
MX2009006529A (en) 2009-08-18
CN101687848A (en) 2010-03-31
JP5315253B2 (en) 2013-10-16
EP2102192A1 (en) 2009-09-23
US20080200516A1 (en) 2008-08-21
EP2102191A1 (en) 2009-09-23
PL2102192T3 (en) 2013-04-30
HK1140483A1 (en) 2010-10-15
CA2674347C (en) 2013-08-06
CA2674358C (en) 2013-10-08
WO2008083341A1 (en) 2008-07-10
RU2009122242A (en) 2011-02-10
MY146462A (en) 2012-08-15
RU2464270C2 (en) 2012-10-20
ES2398846T3 (en) 2013-03-22
NO342530B1 (en) 2018-06-11
NO20092464L (en) 2009-09-28
MX2009006530A (en) 2009-08-18
KR20090086121A (en) 2009-08-10
IL199234A (en) 2013-07-31
AU2007341992A1 (en) 2008-07-10
NZ577129A (en) 2012-02-24
US20080200517A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
MY145936A (en) Solid state forms of racemic ilaprazole
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
MY145632A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2009115562A3 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
ZA200709745B (en) Compositions and methods for inhibiting gastric acid secretion
WO2007134678A3 (en) Triazole derivatives ii
WO2010077101A3 (en) Novel thiazolidinedione derivative and use thereof
MX2009000080A (en) Benzimidazole derivatives as selective acid pump inhibitors.
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
WO2007138468A3 (en) Processes for the preparation of lansoprazole
WO2010117756A3 (en) Substituted benzimidazole pharmaceutical formulations
WO2006067599A3 (en) Stable oral benzimidazole compositions and process of preparation thereof
WO2009096667A3 (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
MXPA05009183A (en) Polymorphs of s-omeprazole.
WO2008015530A3 (en) Stable solid oral formulation of pantoprazole
EP2065379A4 (en) Benzimidazole compound having gastric acid secretion inhibitory activity
WO2008084067A3 (en) Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives
MY140986A (en) S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same